Mathias Schmidt
Company: JCR Pharmaceuticals Co Ltd
Job title: President & Chief Executive Officer
Seminars:
12.00 Presenter Q+A & Audience Discussion 12:00 pm
What do we mean by 'next generation' antibodies and how can we enhance their clinical relevance?Read more
day: Day One Track 1 AM
11.00 Translating Successful Learnings from J-Brain Cargo® to Innovate Second Generation Antibodies with Enhanced BBB Penetration in Other CNS Indications 11:00 am
Outlining rationale for successful development of an antibody shuttle platform to increase brain uptake while managing risks of anaemia Applying transferrin-mediated transcytosis technology to optimize delivery of biologics to treat neurodegeneration, neuroinflammation, and moreRead more
day: Day One Track 1 AM
Exploring Opportunities for Systemic Antisense Delivery with Receptor-Mediated BBB Shuttles 8:00 am
Due to their large size and virus-like nature eliciting immune defences, oligonucleotide therapeutics have been restricted in their ability to be delivered systemically and cross the blood-brain barrier, but what if they could be conjugated to brain-penetrating proteins and shuttled across as cargo? Push the boundaries of ASO delivery beyond intrathecal injection and uncover new…Read more
day: Pre-Conference Day